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Selective reuptake inhibitors (SSRIs), such as fluoxetine and sertraline, increase
circulating Transforming-Growth-Factor-β1 (TGF-β1) levels in depressed patients, and
are currently studied for their neuroprotective properties in Alzheimer’s disease. TGF-β1
is an anti-inflammatory cytokine that exerts neuroprotective effects against β-amyloid
(Aβ)-induced neurodegeneration. In the present work, the SSRI, fluoxetine, was tested
for the ability to protect cortical neurons against 1 µM oligomeric Aβ1-42-induced
toxicity. At therapeutic concentrations (100 nM–1 µM), fluoxetine significantly prevented
Aβ-induced toxicity in mixed glia-neuronal cultures, but not in pure neuronal cultures.
Though to a lesser extent, also sertraline was neuroprotective in mixed cultures, whereas
serotonin (10 nM–10 µM) did not mimick fluoxetine effects. Glia-conditioned medium
collected from astrocytes challenged with fluoxetine protected pure cortical neurons
against Aβ toxicity. The effect was lost in the presence of a neutralizing antibody
against TGF-β1 in the conditioned medium, or when the specific inhibitor of type-1
TGF-β1 receptor, SB431542, was added to pure neuronal cultures. Accordingly, a 24 h
treatment of cortical astrocytes with fluoxetine promoted the release of active TGF-
β1 in the culture media through the conversion of latent TGF-β1 to mature TGF-β1.
Unlike fluoxetine, both serotonin and sertraline did not stimulate the astrocyte release of
active TGF-β1. We conclude that fluoxetine is neuroprotective against Aβ toxicity via a
paracrine signaling mediated by TGF-β1, which does not result from a simplistic SERT
blockade.
Keywords: Alzheimer’s disease, β-amyloid, neuroprotection, antidepressants, fluoxetine, cortical neurons, TGF-
β1, depression
INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by memory loss, cognitive
decline, and neuropsychiatric symptoms able to interfere with normal daily activities (Ballard et al.,
2009). The ‘amyloid cascade hypothesis’ remains a widely accepted explanation of the etiology of
AD also after recent revisions (Selkoe and Hardy, 2016). According to this hypothesis, the earliest
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event in the pathogenic cascade leading to dementia is the
formation of aggregates of a 42-amino acid peptide called
β-amyloid peptide (Aβ1-42). It is generally believed that
oligomeric species of Aβ1-42 represent the key initiators of a
complex pathogenic cascade that cause hyperphosphorylation
of tau protein, synaptic dysfunction and finally neuronal
death (Giacobini and Gold, 2013; Musiek and Holtzman,
2015). Soluble Aβ oligomers are highly toxic species that
disrupt synaptic function and their burden correlates better
with dementia severity than insoluble fibrillar deposits
(Selkoe and Hardy, 2016). The neurotoxic effects of Aβ
oligomers have been investigated in vitro, with different
molecular mechanisms possibly explaining these effects,
such as the amplification of NMDA toxicity (Hynd et al.,
2004), the loss of the canonical Wnt signaling (Caricasole
et al., 2004) and the activation of cell cycle in differentiated
neurons (reviewed by Herrup et al., 2004). Neurotrophic
factors, which seem to be deficient in the AD brain,
including Brain-derived Neurotrophic Factor (BDNF)
(Castren and Tanila, 2006), Nerve Growth Factor (NGF)
(Iulita et al., 2016) and Transforming-Growth-Factor-
β1 (TGF-β1) (Wyss-Coray, 2006; Caraci et al., 2011a),
have been proposed to limit the neurotoxicity of Aβ
oligomers.
TGF-β1 is a neurotrophic factor that exerts neuroprotective
effects against β-amyloid-induced neurodegeneration
(Caraci et al., 2008), and a selective impairment of TGF-
β1 signaling pathway has been demonstrated in the early
phase of AD pathogenesis (Tesseur et al., 2006). The +10
CC genotype of TGF-β1 gene, which affects the levels of
expression of TGF-β1, increases the risk to develop Late-
Onset AD, and is also associated with depressive symptoms
in AD (>5-fold risk) (Caraci et al., 2012). Hence, a deficit
of TGF-β1 seems to be a common pathophysiological
event in both depression and AD (Caraci et al., 2010,
2014).
Depression is a risk factor for the development of AD,
and the presence of depressive symptoms significantly increases
the conversion of Mild Cognitive Impairment (MCI) into
AD (Modrego and Ferrández, 2004). In animal models
of amyloid -induced neurodegeneration Aβ1-42 can induce
both a depressive state and memory deficits as observed
in rodents (Colaianna et al., 2010; Morgese et al., 2014;
Tucci et al., 2014). Interestingly, a continued long-term
treatment with antidepressants reduces the risk to develop
AD (Kessing et al., 2009). Among antidepressants, selective
reuptake inhibitors (SSRIs), such as fluoxetine and sertraline,
increase circulating TGF-β1 levels, which are reduced in major
depressed patients (Lee and Kim, 2006; Sutcigil et al., 2007).
Whether SSRIs cater the potential to be neuroprotective in
AD, by rescuing TGF-β1 signaling, remains to be determined.
Evidence exists that fluoxetine prevents amyloid pathology and
reverses memory impairment in different animal models of
AD (Wang et al., 2014; Jin et al., 2016). Here, we tested
fluoxetine for its potential neuroprotective activity against
Aβ toxicity and the prospective role of TGF-β1 in this
phenomenon.
MATERIALS AND METHODS
Handling of Aβ and Preparation of
Human Aβ Oligomers
Synthetic human Aβ1-42 oligomers were prepared according to
the original protocol of Klein’s group (Gong et al., 2003). Briefly,
the Aβ1-42 lyophilized peptide, purchased from Novas Biologicals
(Littleton, CO, USA), was dissolved in trifluoroacetic acid (TFA)
(1 mg/ml) and sonicated in a water bath sonicator for 10 min.
Then, TFA was evaporated under a gentle stream of argon, and
1 ml 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) was added to the
peptide. After 1 h incubation at 37◦C, the peptide solution was
dried under a stream of argon, and then solubilized again by
adding 2 ml of HFIP. Finally, HFIP was removed by argon
streaming followed by further drying in a lyophilizer for 1 h, and
Aβ1-42 then suspended in 5 mM anhydrous dimethyl sulfoxide
(DMSO) before dilution to 100 µM in ice-cold cell culture
medium DMEM-F12. Samples of Aβ1-42 at the concentration
of 100 µM were incubated for 72 h at 4◦C and then stored
at −20◦C until use. Aβ1-42 oligomers were used in neuronal
cultures at a final concentration of 1 µM in the presence of the
glutamate receptor antagonists MK-801 (10 µM) and DNQX
(30 µM) to avoid the potentiation of endogenous glutamate
toxicity.
Drugs
Fluoxetine and sertraline were purchased from Sigma–Aldrich
(St Louis, MO, USA). SB431542 and ARP-100 were purchased
from Tocris (Bristol, UK). All the compounds were dissolved
in DMSO at the initial concentration of 10 mM. The final
concentration of DMSO applied to the cultures was 0.1%.
Serotonin was purchased from Sigma–Aldrich (St Louis, MO,
USA) and dissolved in PBS. The neutralizing antibody specific
for TGF-β1 was purchased from R&D system (Minneapolis, MN,
USA), was reconstituted in sterile PBS and used in neuronal
cultures at a final concentrations of 2 µg/ml.
Cultures of Cortical Neurons and
Assessment of Neuronal Injury
Cultures of pure cortical neurons were obtained from rats at
embryonic day 15 (Harlan Laboratories, Italy). Briefly, cortices
were dissected in Ca++/Mg++ free buffer and mechanically
dissociated. Cortical cells were plated at a density of 2× 106/dish
on 35 mm dishes (Nunc, Rochester, NY, USA) pre-coated with
0.1 mg/ml poly-D-lysine (St Louis, MO, USA) in DMEM/Ham’s
F12 (1:1) medium supplemented with the following components:
10 mg/ml bovine serum albumin, 10 µg/ml insulin, 100 µg/ml
transferrin, 100 µM putrescine, 20 nM progesterone, 30 nM
selenium, 2 mM glutamine, 6 mg/ml glucose, 100 U/ml penicillin,
and 100 µg/ml streptomycin. Cytosine-D-arabinofuranoside
(10 µM) was added to the cultures 18 h after plating to avoid
the proliferation of non-neuronal elements and was kept for
3 days before medium replacement. This method yields >99%
pure neuronal cultures, as judged by immunocytochemistry
for glial fibrillary acidic protein and flow cytometry for
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neuron-specific microtubule-associated protein 2 (Copani et al.,
1999).
For mixed cortical cultures, cortical cells were grown into
DMEM/F12 (1:1) supplemented with 10% horse serum, 10% fetal
calf serum (FCS), 2 mM glutamine, 6 mg/ml glucose. After 7–
10 days in vitro, glia cell division was halted by exposure to 10 µM
cytosine-D-arabinoside for 3 days and cells were shifted into
a maintenance serum-free medium. Mature cultures contained
about 35–40% neurons.
Neuronal cultures were treated at 7 days in vitro with Aβ1-42
oligomers (1 µM) for 48 h both in the presence and in the absence
of fluoxetine (100 nM – 1 µM). Neuronal injury was assessed
by the methyltetrazolium test (MTT) assay in pure neuronal
cultures, and Trypan Blue staining in mixed neuronal cultures
48 h after Aβ1-42 treatment. For MTT assay cells were incubated
with MTT (0.9 mg/ml final concentration, St Louis, MO, USA)
for 2 h at 37◦C. A solubilization solution containing 20% SDS was
then added for an additional 1 h and formazan production was
evaluated in a plate reader (λ = 560 nm). Aβ toxicity in mixed
neuronal cultures was assessed by counting dead neurons stained
with Trypan blue. Stained neurons were counted in three random
microscopic fields/well.
PURE CULTURES OF CORTICAL
ASTROCYTES
Cortical glial cells were prepared from 1- to 3-day-old Sprague-
Dawley rats. After removal of meninges and isolation of cortices,
cells were dispersed by mechanical and enzymatic dissociation
using a 0.25% solution of trypsin (Invitrogen). Cells were plated
onto 75-mm2 flasks and maintained in DMEM, supplemented
with 10% fetal calf serum, penicillin/streptomycin (100 U/ml–
100 g/ml), and glutamine (2 mM). All medium constituents were
from Invitrogen, and all plastic materials were from Corning Life
Sciences (Lowell, MA, USA). Confluent cultures at 8–10 days
in vitro were shaken overnight at 37◦C to remove microglia and
oligodendrocytes. Astrocytes were collected by trypsin digestion,
seeded onto 35- or 100-mm dishes, and used for experiments
6–8 days after replating.
Determination of TGF-β1 Levels in the
Astrocyte Medium
Astrocyte-conditioned medium was collected and subjected to
acid treatment procedure. Samples were acidified to a pH
of approximately 2.6 with 1 N HCl for 15 min at room
temperature, then neutralized to approximately pH 7.6 with 1
N NaOH. Levels of TGF-β1 released into the medium were
measured by enzyme-linked immunosorbent assay using the
TGFβ1 Emax Immunoassay System (Promega, Madison, WI,
USA), based on an antibody sandwich format, strictly following
the manufacturer’s instructions.
In brief, 96-well plates were coated overnight at 4◦C with
primary monoclonal anti-TGF-β1 antibody. A blocking solution
was added for 35 min at 37◦C before incubation with samples and
standards for 90 min at room temperature, to allow binding of
soluble TGF-β1. A primary polyclonal anti-TGF-β1 antibody was
then added for 2 h to bind captured TGF-β1. Finally, specifically
bound polyclonal antibody was detected by incubation for 2 h
with a horseradish peroxidase-conjugated secondary antibody.
Wells were extensively washed between each step. After a final
10-min incubation with achromogenic substrate solution, the
resulting redox reaction was stopped by acidification with 1N
HCl, and absorbance was immediately measured at 450 nm. The
assay is sensitive in the range of 32–1000 pg/ml.
Western Blot
Western blot analyses was performed as previously described
(Caraci et al., 2015a) on neurons or astrocytes harvested at 4◦C
in RIPA buffer in the presence of a cocktail of protease inhibitors
(Sigma–Aldrich P2714), serine/threonine phosphatase inhibitors
(Sigma–Aldrich, P0044) and tyrosine protein phosphatases
inhibitors (Sigma–Aldrich, P5726). Protein concentrations were
determined by Bradford’s method using bovine serum albumin
as a standard. After blocking, membranes were incubated with
the following primary antibodies overnight at 4◦C: rabbit anti-
TGF-β1 (Abcam 25121, Cambridge, UK; 1:1000), rabbit anti-
MMP2 (Santa Cruz Biotechnology, Santa, CA, USA; 1:500) and
mouse anti-α-Tubulin and anti-β-Actin (Sigma–Aldrich; 1:500).
Secondary goat anti-rabbit labeled with IRDye 680 (1:30.000 Li-
COR Biosciences) and goat anti-mouse labeled with IRDye 800
(1:25.000 Li-COR Biosciences) were used at RT for 45 min.
Hybridization signals were detected with the Odyssey Infrared
Imaging System (LI-COR Biosciences). Western blot data were
quantified by densitometric analysis of the hybridization signals
in four different blots per experiment.
Gene Expression Analysis by Real-Time
RT-PCR
Total RNA was isolated from cultured astrocytes treated
with fluoxetine (1 µM) using TRIzol reagent (Invitrogen),
GenEluteTM Mammalian Total RNA Miniprep Kit and
DNASE70-On-Column DNase I Digestion Set (St Louis,
MO, USA) as previously described (Benatti et al., 2011). Two
milligrams of total RNA was reverse transcribed with High
Capacity cDNA Reverse Transcription Kit (Life Technologies
Corporation, Carlsbad, CA, USA) in 20 µl of reaction mix.
Real Time RT-PCR was performed in Roche Light Cycler R© 480
(Roche Diagnostics GmbH, Roche Applied Science, Mannheim,
Germany) using Power UP SYBR Green mix (Life Technologies
Corporation, Carlsbad, CA, USA). The following forward and
reverse primers were used at the final concentration of 300 nM:
TGF-β1 (NM_021578.2) Forward 5′-CCTTGCCCTCTACAACC
AAC-3′, Reverse 5′-CTTGCGACCCACGTAGTAGAC-3′; Mmp
-2 (NM_031054.2) Forward 5′-AGTTCTGGAGATACAATGAA
G-3′, Reverse 5′-TCTCCAACTTCAGGTAATAAG-3′; glycera
-ldehydes-3-phosphate dehydrogenase GAPDH (NM_017008.4)
Forward 5′-CAAGGTCATCCATGACAACTTTG-3′, Reverse
5′-GGGCCATCCACAGTCTTCTG-3′. Single PCR products
were subjected to a heat dissociation protocol as previously
described (Alboni et al., 2013). Ct (cycle threshold) value
was determined by the Light Cycler R© 480 Software (Roche
Diagnostics GmbH, Roche Applied Science, Mannheim,
Germany) mRNA expression was calculated with the 11Ct
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method with GAPDH as endogenous control. Two independent
experiments were performed.
Statistics
All experiments were blind with respect to treatment. Data were
expressed as mean ± standard error mean (SEM). Statistical
analysis was performed using dedicated software (GraphPad
Prism, GraphPad Software). Data obtained from neuronal
cultures and neuronal cell counts have been analyzed using a one-
way ANOVA. The post hoc Bonferroni test was used for multiple
comparisons; for western blot and gene expression analysis we
used unpaired Student’s t-test; p-values<0.05 were considered as
significant.
Study Approval
The study was authorized by the Institutional Animal Care and
Use Committee (IACUC) of the University of Catania (OPBA
Project #169/2013). Animal care followed Italian (D.M.116192)
and EEC (O.J. of E.C. L 358/1 12/18/1986) regulations on
protection of animals used for experimental and scientific
purposes.
RESULTS
Both pure and mixed rat neuronal cultures were challenged with
synthetic Aβ1-42 oligomers (1 µM) for 48 h. Because Aβ1-42 is
able to potentiate glutamate toxicity, experiments were carried
out in the presence of a cocktail of ionotropic glutamate receptor
antagonists [MK-801 (1 µM) and DNQX (30 µM)] to exclude
the contribution of endogenous excitotoxicity to the overall
process of neuronal death. Under these conditions, neurons
exposed to Aβ oligomers die showing an apoptotic phenotype
(Copani et al., 1999; Caraci et al., 2015b). Exposure to Aβ1-42
oligomers (1 µM) was toxic in a time dependent manner,
inducing apoptotic neuronal death in about 20–25% of neuronal
population at 24 h, and 35–45% at 48 h. Fluoxetine or sertraline
were co-applied with Aβ1-42 for 48 h at the concentrations
(100 nM–10 µM) observed in depressed patients treated with
these drugs. Fluoxetine (1–10 µM) prevented Aβ toxicity in
mixed neuronal cultures (Figure 1B), but not in pure neuronal
cultures (Figure 1A). Though to a lesser extent, also sertraline was
neuroprotective in mixed cultures only (Figure 1A), suggesting
that glial cells are essential to mediate the neuroprotective effects
of both fluoxetine and sertraline. SSRIs, including fluoxetine
and sertraline, block the serotonin transporter (SERT) that is
located on the cell bodies and terminals of 5-HT neurons, as
well as on cortical astrocytes (Inazu et al., 2001). Since SERT
blockade results into an increased availability of serotonin, we
tested serotonin (10 nM–10 µM) as a potential mediator of
neuroprotection. As different from fluoxetine and sertraline,
serotonin was devoid of effects (Figure 1C).
To understand the role of glial cells into the neuroprotective
effects of SSRIs, we treated pure rat cortical astrocytes, the
main source of TGF-β1 in CNS, with fluoxetine (1 µM) for
6 h or 24 h. In astrocytes, fluoxetine did not modify TGF-
β1 mRNA levels at 6 h (Figure 2A), whereas it induced an
FIGURE 1 | Fluoxetine and sertraline prevent Aβ1-42-induced toxicity
only in the presence of glial cells. Antidepressant drugs were applied at
increasing concentrations (100 nM–10 µM) both to pure (A) and mixed
cortical neurons (B) in co-treatment with Aβ1-42 oligomers (1 µM) for 48 h.
(A) Aβ toxicity in pure neuronal cultures is expressed as percentage of
neuronal survival (quantified by MTT assay). Values in pure cortical neurons
are means ± SEM of six to nine determinations ∗p < 0.05 vs. control (C)
(One-way ANOVA + Bonferroni’s test). (B) Aβ toxicity in mixed neuronal
cultures was assessed by cell counting after trypan blue staining. Cell count
(Continued)
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FIGURE 1 | Continued
was performed in three random microscopic fields/well. Values in mixed cortical
neurons are expressed as percentage of Aβ1-42 toxicity (vhl) and are means ±
SEM of twelve determinations ∗p < 0.05 vs. Aβ alone (One-way ANOVA +
Bonferroni’s test). (C) Serotonin (10 nM–10 µM) was co-applied with Aβ1-42
oligomers (1 µM) to mixed neuronal cultures for 48 h. The effects of serotonin
against Aβ toxicity in mixed neuronal cultures were assessed by cell counting
after trypan blue staining.
increased synthesis of the precursor of TGF-β1 (Pro-TGF-β1) at
24 h (Figure 2B). In addition, we found significantly increased
levels of active TGF-β1(101 pg/ml) in the medium of cultured
astrocytes exposed to fluoxetine (1 µM) for 24 h with respect to
untreated astrocytes (53,4 pg/ml) (Figure 2C). Neither sertraline
nor serotonin stimulated the release of active TGF-β1 from
cortical astrocytes (Figure 2C). These data suggested that, at least
in the case of fluoxetine, the neuroprotective activity against Aβ
could be mediated by astrocytes through the release of significant
amounts of active TGF-β1.
To ascertain the contribution of astrocytes to the effect
of fluoxetine, pure neuronal cultures were exposed to a glial
conditioned medium (GCM) (i.e., medium collected from
cultures of cortical astrocytes 24 h after a transient exposure to
1 µM fluoxetine or vehicle) before the treatment with Aβ1-42
oligomers. GCM collected from astrocytes challenged with
fluoxetine protected pure cortical neurons against Aβ toxicity
(Figure 3). A TGF-β1 neutralizing antibody (2 µg/ml), added
to the astrocyte cultures, abolished the protective activity of
the GCM derived from fluoxetine-treated astrocytes (Figure 3).
Finally, both TGF-β1 antibodies and the specific inhibitor of type-
1 TGF-β1 receptor, SB431542, (Laping et al., 2002) prevented the
neuroprotective activity of fluoxetine directly applied to mixed
cultures challenged with Aβ1-42 oligomers (Figure 4). SB431542
and anti-TGF-β1 had no effect on neuronal viability in the
absence of Aβ1-42 (Figure 4). All together, these data demonstrate
that the protective effect of fluoxetine on Aβ-treated neurons was
mediated by an increased release of active TGF-β1 from cortical
astrocytes.
FIGURE 2 | Fluoxetine increases the expression of pro-TGF-β1 and the release of active TGF-β1 from cortical astrocytes. (A) TGF-β1 mRNA levels
obtained by Real-time RT-PCR in cultured astrocytes transiently exposed to fluoxetine (Flx; 1 µM) for 6 h are shown. Values were normalized by endogenous GAPDH
mRNA levels and are represented as means + SEM for n = 4 for two independent experiments. (B) Representative immunoblots of pro-TGF-β1 (about 55 kDa) in
total protein extracts from rat cortical astrocytes exposed to fluoxetine (Flx; 1 µM) for 24 h. Bars refer to the means ± SEM of the densitometric values of pro-TGF-β1
bands normalized against β-actin. Each experiment was repeated four times; ∗p < 0.05 vs. control by Student’s t-test. (C) Levels of active TGF-β1 in the medium of
cultured astrocytes exposed for 24 h to fluoxetine (Flx; 1 µM), sertraline (Srt; 1 µM) or to increasing concentrations of serotonin (100 nM–10 µM) are shown. Values
are means ± SEM of nine determinations; ∗p < 0.05 (Student’s t-test) versus untreated control astrocytes.
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FIGURE 3 | Fluoxetine prevents Aβ toxicity via a paracrine mechanism mediated by TGF-β1. Pure cultures of rat cortical neurons were exposed to glial
conditioned medium (GCM) collected from cortical astrocytes 24 h after a transient (1 hr) exposure to1 µM fluoxetine or vehicle. Neurons were then treated with
Aβ1-42 oligomers (1 µM) for 48 h in the presence or absence of anti-TGF-β1 antibody. A schematic drawing of this experimental protocol is shown in the upper
panel. Anti-TGF-β1 was added at a concentration of 2 µg/ml just before transferring of GCM into pure neuronal cultures. Aβ toxicity in pure neuronal cultures was
assessed by MTT assay and is expressed as percentage of neuronal survival. Values are means ± SEM of 12–15 determinations ∗p < 0.05 vs. control (GCM, vhl);
#p < 0.05 vs. Aβ1-42 alone (GCM, Aβ1-42, vhl); ∗∗p < 0.05 vs. Aβ1-42 and fluoxetine (GCM, Aβ1-42, Flx) (One-way ANOVA + Bonferroni’s test).
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FIGURE 4 | The neuroprotective effects of fluoxetine against
Aβ1-42-induced toxicity are mediated by TGF-β1. Mixed cortical cultures
were challenged with Aβ1-42 oligomers (1 µM) for 48 h in the absence or
presence of fluoxetine (1 µM) applied alone or combined with the selective
inhibitor of Smad-dependent TGF-β1 signaling, SB431542 (SB; 10 µM) or
with a neutralizing antibody specific for TGF-β1 (anti-TGF-β1) applied at a
concentration of 2 µg/ml. Aβ toxicity in mixed neuronal cultures was assessed
by cell counting after trypan blue staining. Cell counts was performed in three
random microscopic fields/well. Values are expressed as percentage of
Aβ1-42 toxicity and are means ± SEM of nine determinations ∗p < 0.05 vs. Aβ
alone (Aβ1-42, vhl) and #Aβ + fluoxetine (Aβ1−42, Flx, vhl) (One-way ANOVA +
Bonferroni’s test).
TGF-β1 activity is primarily regulated through the conversion
of latent TGF-β1 to active TGF-β1 by a variety of proteases
(Annes et al., 2003), among which Matrix Metalloproteinase
2 (MMP-2), that is highly expressed in astrocytes (Li et al.,
2011) and Matrix Metalloproteinase 9 (MMP-9) play a central
role in this conversion (Jenkins, 2008). We examined the
effects of fluoxetine on MMP-2 expression and activation in
cortical astrocytes (Figure 5). Fluoxetine did not significantly
modify MMP-2 mRNA levels at 6 h (Figure 5A), whereas it
induced an increased expression of the active form of MMP-
2 (66 kDa) at 24 h (Figure 5B). These data indicate that
fluoxetine promoted the release of neuroprotective TGF-β1 by
favoring the activation of MMP-2 and the ensuing maturation of
latent TGF-β1. Accordingly, the GCM collected from fluoxetine-
treated astrocytes in the presence of ARP-100, a selective
inhibitor of MMP-2 at nanomolar concentrations (Tuccinardi
et al., 2006), failed to protect pure cortical neurons against
Aβ toxicity (Figure 5C). ARP-100 was also able to prevent
the neuroprotective of fluoxetine when directly added to mixed
cultured challenged with Aβ and it had no effect on neuronal
viability in the absence of Aβ (Figure 5D).
DISCUSSION
Neuronal cultures challenged with synthetic analogs of human
oligomers of Aβ1-42 are considered a widely accepted and reliable
model of the neurodegeneration occurring in AD (Gong et al.,
2003). In the present paper, synthetic human Aβ1-42 oligomers
were prepared according to the original protocol of Klein’s group,
as modified and characterized in Giuffrida et al. (2009). We then
investigated the neuroprotective effects of two second-generation
antidepressants in neuronal cultures challenged for 48 h with
Aβ1-42 oligomers. We found that both fluoxetine and sertraline,
two of the most currently prescribed SSRIs for the treatment of
depression, prevented Aβ-induced neurodegeneration in cultures
containing both neurons and glia, but not in pure neuronal
cultures. Hence, glia cells mediated the neuroprotective effects of
the two drugs.
Serotonin did not mimic the neuroprotective effects of
fluoxetine and sertraline, suggesting that the increased
serotonergic tone resulting from SERT blockade was not
involved in the phenomenon.
Pharmacoepidemiological studies have demonstrated that a
long-term treatment with SSRIs reduces the risk to develop AD
in patients with depression (Kessing, 2012). A chronic treatment
with SSRIs is associated with lower cortical β-amyloid PET signal
in cognitively normal elderly human subjects (Cirrito et al., 2011),
and with some degree of protection against the negative effects of
depression on cognition in AD patients (Rozzini et al., 2010).
In different animal models of neuropsychiatric disorders,
fluoxetine is known to induce the expression of neurotrophic
factors, such as BDNF (Calabrese et al., 2009), insulin-like growth
factor 1 (IGF-1) and glial cell line-derived neurotrophic factor
(GDNF) (Allaman et al., 2011; Tizabi, 2016), whose source and
potential neuroprotective effects remain unclear (Hashioka et al.,
2013).
In the present study, we tested the hypothesis that fluoxetine
and sertraline exert a neuroprotective activity against Aβ toxicity
by stimulating the glia release of TGF-β1. TGF-β1 is known
to prevent Aβ-induced neurodegeneration (Prehn et al., 1996;
Caraci et al., 2008), and it acts as a master regulator of other
neurotrophins (Sometani et al., 2001; Unsicker and Krieglstein,
2002; Schober et al., 2007). Surprisingly, fluoxetine, but not
sertraline, increased the release of active TGF-β1 from cortical
astrocytes. As in the case of other drugs able to induce
TGF-β1 release from astrocytes, including estradiol (Sortino
et al., 2004), and dual orthosteric agonists of metabotropic
glutamate 2 (mGlu2) and mGlu3 receptors (Caraci et al., 2011b),
we found that fluoxetine increased the intracellular levels of
the precursor of TGF-β1 (Pro-TGFβ1) without affecting TGFβ1
mRNA expression. In addition, we demonstrate that fluoxetine
affected the conversion of Pro-TGF-β1 into active TGF-β1,
likely through the activation of MMP-2. The involvement of
MMP-2 in fluoxetine activity is in line with the suggestion
that extracellular matrix modifying enzymes contribute to
antidepressant-mediated structural plasticity in the hippocampus
(Benekareddy et al., 2008; Lee et al., 2014). The evidence
that inhibiting astrocytes MMP-2 resulted into a lack of
neuroprotection against Aβ toxicity supported the role of MMP-2
in fluoxetine-induced TGF-β1 release.
The reason why sertraline, which shares the same therapeutic
target with fluoxetine (i.e., the SERT), did not induce astrocyte
TGF-β1 release remains to be established. Further studies will be
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FIGURE 5 | Role of metalloproteinase-2 (MMP-2) in the neuroprotective effects of fluoxetine against Aβ toxicity. (A) MMP-2 mRNA levels in cultured
astrocytes transiently exposed to fluoxetine (Flx) for 6 h are shown. Values were normalized by endogenous GAPDH mRNA levels and are represented as means
+SEM for n = 4 for two independent experiments. (B) Representative immunoblots of active MMP-2 in total protein extracts from rat cortical astrocytes exposed to
fluoxetine (Flx, 1 µM) for 24 h. Arrows indicate pro-MMP2 (72 kDa) and the active form at about 66 kDa. Bars refer to the means ± SEM of the densitometric values
of MMP-2 bands normalized against α-tubulin. Each experiment was repeated four times ∗p < 0.05 vs. control by Student’s t-test. (C) Pure cultures of rat cortical
neurons were exposed to GCM collected from cortical astrocytes 24 h after a transient (1 hr) exposure to 1 µM fluoxetine with or without ARP-100 (50 nM), before
treatment with Aβ1-42 oligomers (1 µM) for 48 h. Values are means ± SEM of 12–15 determinations ∗p < 0.05 vs. control values obtained with GCM alone (GCM,
vhl), #p < 0.05 vs. GCM+Aβ and ∗∗GCM+Aβ+FLX (One-way ANOVA + Bonferroni’s test). (D) Selective inhibition of MMP-2 prevents the neuroprotective effects of
fluoxetine against Aβ toxicity. Mixed cortical cultures were challenged with Aβ1-42 oligomers (1 µM) for 48 h in the absence or presence of fluoxetine (1 µM) applied
alone or combined with ARP100 (10–100 nM). Values are expressed as percentage of Aβ1-42 toxicity and are means ± SEM of twelve determinations ∗p < 0.05 vs.
Aβ alone and #Aβ+fluoxetine (Aβ1-42, Flx, vhl) (One-way ANOVA +Bonferroni’s test).
necessary to understand the molecular mechanisms underlying
the neuroprotective effects of sertraline in the absence of TGF-β1
release, at least in our experimental model. We cannot exclude
that sertraline could increase TGF-β1 levels in vivo, as observed
in MMD patients, through the interplay between astrocytes and
microglial cells (Hashioka et al., 2009).
Fluoxetine has been studied in different animal models of
neurological disorders, including Parkinson’s disease, Down
syndrome and ischemic brain injury (Zhu et al., 2012; Guidi
et al., 2014; Caiaffo et al., 2016). Different molecular mechanisms
have been proposed to explain its neuroprotective effects,
including BDNF release (Chang et al., 2006), antagonism on
NMDA receptors (Vizi et al., 2013), inhibition of NF-kappa
B activity (Lim et al., 2009), and inhibition of the release of
pro-inflammatory factors (TNF-α, IL-1β) from microglial cells
(Zhang et al., 2012).
In the present work we identified a potential disease-
modifying activity of fluoxetine depending on a paracrine
mechanism mediated by TGFβ1. It is known that fluoxetine,
during therapeutic treatment for major depression, accumulates
in the brain up to a 20 µM concentration (Henry et al.,
2005). Fluoxetine inhibits neuronal SERT with a Ki value of
0.07 µM (Wong et al., 2005), whereas the brain concentration of
fluoxetine is approximately 15–200 times higher than its binding
affinity for SERT. Thus, fluoxetine may interact with additional
pharmacological targets and act on non-neuronal cells to exert
its clinical efficacy (Hashioka et al., 2013). We propose that
stimulation of TGF-β1 release from astrocytes could represent
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an additional therapeutic mechanism for this antidepressant
drug, which warrants further investigations in animal models
of depression and AD. A similar neuroprotective mechanism
may be postulated for venlafaxine, which, at least in astroglia-
microglia co-cultures, stimulates TGF-β1-release (Vollmar et al.,
2008).
Recent studies have demonstrated that a chronic treatment
with fluoxetine prevents amyloid pathology and reverses memory
deficits in two different animal models of AD (Wang et al.,
2014; Jin et al., 2016). Based on the present finding, it would
be relevant to assess whether fluoxetine can reduce AD-
related pathology and prevent cognitive deficits by rescuing
the TGF-β1 signaling. Interestingly, MCI patients treated with
fluoxetine showed improvement in MMSE, and in immediate
and delayed logical memory irrespective of the presence of
depressive symptoms (Mowla et al., 2007). We have recently
identified a key role for TGF-β1 in recognition memory
formation, demonstrating that this neurotrophic factor is
essential for the transition from early to late LTP (Caraci
et al., 2015a). Deficit of TGF-β1 signaling is a primary event
in AD pathogenesis and a reduced expression of type-2 TGF-
β1 receptor specifically correlates with cognitive decline in
early AD patients (Tesseur et al., 2006). Thus, the stimulation
of TGF-β1 release from cortical astrocytes with fluoxetine
might represent a novel pharmacological strategy to yield
neuroprotection in AD.
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